arrow
A

Ashish Kumar

Sir Ganga Ram Hospital
H指数:49
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Genetic Susceptibility Versus Fibrosis Progression in North Indian Metabolic Dysfunction–Associated Steatotic Liver Disease: Distinct Roles of APOC3 and PNPLA3 in a Candidate Gene Study

遗传易感性在北印度代谢功能障碍相关脂肪性肝病中的差异与纤维化进展:候选基因研究中APOC3和PNPLA3的不同作用

2026-08-210
PRE
A multicentre survey of liver fibrosis burden in type 2 diabetes in India: the DiaFib-Liver Study

一项关于印度2型糖尿病患者肝纤维化负担的多中心调查:DiaFib-Liver研究

2026-03-260
OAAI
Indian National Association for the Study of the Liver Position Statements on Prevention, Diagnosis, and Management of Hepatitis B Virus Infection in India

印度国家肝脏研究协会关于乙型肝炎病毒感染预防、诊断和管理的立场声明

2025-06-090
PRE
Adoption of the New Nomenclature of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) by the Indian National Association for Study of the Liver (INASL): Implications for the INASL Guidance Paper on NAFLD

印度肝病研究全国协会(INASL)采纳代谢功能障碍相关脂肪性肝病(MASLD)的新命名法:对INASL非酒精性脂肪性肝病(NAFLD)指南的影响

2025-05-160
PRE
Clinical and hemodynamic outcomes of self-expanding and balloon-expandable valves for valve-in-valve transcatheter aortic valve implantation (ViV-TAVI): An updated systematic review and meta-analysis

自膨胀瓣膜和球囊扩张瓣膜用于瓣中瓣经导管主动脉瓣植入术(ViV-TAVI)的临床和血流动力学结局:一项更新的系统评价和荟萃分析

2025-04-010
OAAI
Acute-on-chronic liver failure (ACLF): the 'Kyoto Consensus'-steps from Asia

急慢性肝衰竭(ACLF):来自亚洲的“京都共识”进展

2025-02-170
OAAI